Digma Medical Secures $27 Million in Funding to Revolutionize Type 2 Diabetes Treatment with Endoscopic Glycemic Management (EGM)

Digma Medical is excited to announce the successful closure of $27 million in funding, marking a significant milestone in our mission to revolutionize diabetes care. As a pioneering force in the field, Digma is committed to harnessing the potential of the small intestine to deliver safe, simple, and effective therapies for type 2 diabetes, ultimately enhancing the quality of life and long-term health outcomes for patients. Our groundbreaking therapy, Endoscopic Glycemic Management (EGM), targets the duodenal submucosa — a vital area for nutrient sensing and metabolic signaling — with the aim of restoring the body's natural capacity to regulate blood glucose levels. This minimally invasive treatment is designed to be compatible with standard gastrointestinal endoscopes, allowing the EGM procedure to be performed in conventional GI endoscopy suites without the need for additional imaging equipment. With this latest funding, we are furthering our commitment to providing patients with durable glycemic control improvements while minimizing side effects and reducing the need for additional daily medications. The EGM procedure is currently undergoing clinical evaluations, and we look forward to sharing our progress with the medical community and patients alike. At Digma Medical, we believe that our innovative approach has the potential to redefine the management of type 2 diabetes, and we invite those interested in our clinical program to reach out for more information. Together, we can pave the way for a better future in diabetes therapy.